Motley Fool Australia

Alterity Therapeutics Ltd (ASX: ATH) Share Price and News

Price
Movement
52 Week Range
-
1 Year Return
(20 mins delayed)

() Chart and Price Data

.

Share Price
Previous Close
Volume
Day Change
Open
Monthly Average Volume
52 Week Range -
Days Range -
Turnover

Fundamental Company Figures

Data provided by Morningstar.
Market Cap $70.86 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 2.08 billion
Earnings per share -0.015
Dividend per share N/A
Year To Date Return 16.13%
Earnings Yield N/A
Franking N/A

Alterity Therapeutics Ltd (ASX: ATH) Latest News

Here’s why the Alterity Therapeutics (ASX:ATH) share price blasted 20% higher today

More »

miniature rocket breaking out of golden egg representing rocketing share price

Why Alterity Therapeutics (ASX:ATH) share price has surged up 27% today

More »

falling asx share price represented by woman making sad face

Alterity (ASX:ATH) share price lower on completed placement

More »

Why Alterity Therapeutics’ share price has rocketed 96% in 2 days

More »

Investor riding a rocket blasting off over a share price chart

Alterity Therapeutics share price rockets 70% on new data

More »

Businessman with block letter spelling out 'demand' resting on his palm

Why Etherstack and these shares were the most traded on the ASX last week

More »

Recent Stock Announcements

Price Sensitive Only$An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Show All
Date Heading $An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security. Time Pages File Size
 

About Alterity Therapeutics Ltd (ASX: ATH)

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaboration with Takeda for the treatment of Parkinson's disease gastrointestinal neuropathology. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434).

Share Price History

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
03 Mar 2021 $0.03 $0.00 0.00% 14,464,154 $0.04 $0.04 $0.03
02 Mar 2021 $0.04 $0.00 0.00% 5,475,957 $0.04 $0.04 $0.04
01 Mar 2021 $0.04 $0.00 0.00% 5,632,563 $0.04 $0.04 $0.04
26 Feb 2021 $0.04 $0.00 0.00% 6,325,411 $0.04 $0.04 $0.04
25 Feb 2021 $0.04 $0.00 0.00% 4,405,947 $0.04 $0.04 $0.04
24 Feb 2021 $0.04 $0.00 0.00% 13,433,179 $0.04 $0.04 $0.04
23 Feb 2021 $0.04 $0.00 0.00% 8,757,624 $0.04 $0.04 $0.04
22 Feb 2021 $0.04 $0.00 0.00% 8,198,137 $0.04 $0.04 $0.04
19 Feb 2021 $0.04 $0.00 0.00% 9,739,144 $0.04 $0.04 $0.04
18 Feb 2021 $0.04 $0.00 0.00% 8,859,005 $0.04 $0.04 $0.04
17 Feb 2021 $0.04 $0.00 0.00% 7,105,180 $0.04 $0.05 $0.04
16 Feb 2021 $0.04 $0.00 0.00% 13,409,253 $0.04 $0.05 $0.04
15 Feb 2021 $0.05 $0.00 0.00% 36,434,439 $0.04 $0.05 $0.04
12 Feb 2021 $0.04 $0.00 0.00% 8,329,252 $0.04 $0.04 $0.04
11 Feb 2021 $0.04 $0.00 0.00% 29,723,978 $0.04 $0.04 $0.04
10 Feb 2021 $0.04 $-0.01 -20.83% 49,530,588 $0.05 $0.05 $0.04
09 Feb 2021 $0.05 $0.01 25.64% 167,139,689 $0.05 $0.05 $0.05
08 Feb 2021 $0.04 $0.00 0.00% 5,360,740 $0.04 $0.04 $0.04
05 Feb 2021 $0.04 $0.00 0.00% 14,439,306 $0.04 $0.04 $0.04
04 Feb 2021 $0.04 $0.00 0.00% 49,414,230 $0.04 $0.04 $0.04
03 Feb 2021 $0.04 $0.00 0.00% 5,341,720 $0.04 $0.04 $0.03
02 Feb 2021 $0.03 $0.00 0.00% 5,069,099 $0.04 $0.04 $0.03
Show more

Director Transactions

Data provided by Morningstar.
Date Director Type Amount Value Notes
18 Sep 2020 David Sinclair Issued 7 $378,000
18 Sep 2020 Geoffrey Kempler Issued 14 $756,000
18 Sep 2020 Brian Meltzer Issued 7 $378,000
18 Sep 2020 Peter Marks Issued 7 $378,000
18 Sep 2020 Lawrence Gozlan Issued 7 $378,000
18 Sep 2020 Tristan Edwards Issued 7 $378,000


Directors & Management

Data provided by Morningstar.
Name Title StartDate Profile
Mr David Sinclair Non-Executive Director Apr 2019
Mr Geoffrey Paul Kempler Non-Executive Chairman,Non-Executive Director Jun 2005
Mr Brian Derek Meltzer Non-Executive Director Dec 1999
Mr Peter Ashley Marks Non-Executive Director Jul 2005
Mr Lawrence Gozlan Non-Executive Director Aug 2011
Mr Tristan Edwards Non-Executive Director Apr 2019
Mr Phillip Hains Company Secretary May 2014
Dr David Stamler Chief Executive Officer Jan 2021
David Stamler Chief Executive Officer
Kathryn Andrews Chief Financial Officer
David Stamler Chief Medical Officer and Senior Vice President Clinical Development
Phillip Hains Company Secretary
Show more

Top Share Holders

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 523,867,497 48.28%
Life Biosciences Llc 269,905,533 24.88%
Baywick Proprietary Limited <The Retail Discretionary A/C> 14,165,000 1.31%
J P Morgan Nominees Australia Pty Limited 8,041,588 0.74%
Citos Super Pty Ltd <Citos Pty Ltd Sf A/C> 5,000,000 0.46%
Donatello Nizzi 4,678,362 0.43%
Mr James V Babcock 3,980,263 0.37%
Citicorp Nominees Pty Limited 3,705,746 0.34%
The Entrust Group Inc <Robert Davidow Ira A/C> 3,598,740 0.33%
Fagan Harris Pty Ltd <Fagan Harris Super Fund A/C> 3,249,715 0.30%
Mr Christopher Ferris 3,000,000 0.28%
NRB Developments Pty Ltd 2,970,000 0.27%
Capuano Nominees Pty Ltd <The Hartman Investment A/C> 2,750,000 0.25%
One Lucky Oak Pty Ltd <Oakshott Fam Super Fund A/C> 2,200,342 0.20%
Rentuk Shore Pty Ltd 2,128,205 0.20%
Mr Lukasz Pieprzyk 2,022,681 0.19%
Mr Mark Victor Gordon + Miss Linda June Grace Gordon <Mark Gordon R/F Account> 2,000,000 0.18%
Mr Shaun Anthony Neilsen 2,000,000 0.18%
Ms Pamela Joy Bates 2,000,000 0.18%
Moubray Pty Ltd <Robert Hallas Sf A/C> 2,000,000 0.18%
Show more